With 1.2 million shares changed hands, the volume of the stock remained heavier than its average volume of 0.85 million shares. During the session, the Biotechnology company that operates in wider Healthcare sector, reached to the highest price of $6.19 whereas the lowest price it dropped to was $5.02. The 52-week range on SLRN shows that it touched its highest point at $9.25 and its lowest point at $3.36 during that stretch. It currently has a 1-year price target of $11.17. Beta for the stock currently stands at 2.05.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of SLRN was down-trending over the past week, with a drop of -13.28%, but this was down by -15.13% over a month. Three-month performance surged to 24.94% while six-month performance rose 11.45%. The stock lost -42.02% in the past year, while it has lost -30.83% so far this year. A look at the trailing 12-month EPS for SLRN yields -2.68 with Next year EPS estimates of -2.03. For the next quarter, that number is -0.90. This implies an EPS growth rate of 50.32% for this year and 24.61% for next year.
Float and Shares Shorts:
At present, 97.87 million SLRN shares are outstanding with a float of 74.25 million shares on hand for trading. On 2024-10-31, short shares totaled 4.7 million, which was 471.0 higher than short shares on 1727654400. In addition to Ms. Melanie Gloria B.S.N. as the firm’s Chief Operating Officer, Mr. Gilbert M. Labrucherie J.D. serves as its CFO & Chief Business Officer.
Institutional Ownership:
Through their ownership of 1.02937 of SLRN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2024-09-30, SLRN reported revenue of $0.0 and operating income of -$93025000.0. The EBITDA in the recently reported quarter was -$92909000.0 and diluted EPS was -$0.86.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for SLRN since 14 analysts follow the stock currently. There are 9 analysts who recommend BUY ratings, while 0 suggest SELL ratings. Of the remaining analysts, 5 believe that the stock is worth HOLDING, 0 give it an OVERWEIGHT rating, and 0 thinks that it’s UNDERWEIGHT. In the same way, a target price assigned to a stock can also reveal much about its potential. With SLRN analysts setting a high price target of 20.0 and a low target of 6.0, the average target price over the next 12 months is 11.16667. Based on these targets, SLRN could surge 287.6% to reach the target high and rise by 16.28% to reach the target low. Reaching the average price target will result in a growth of 116.41% from current levels.
Analysts have provided yearly estimates in a range of -$2.2607 being high and -$3.45152 being low. For SLRN, this leads to a yearly average estimate of -$2.86541. The surprise factor in the prior quarter was -$0.66. Based on analyst estimates, the high estimate for the next quarter is -$0.35 and the low estimate is -$0.5. The average estimate for the next quarter is thus -$0.43.
